{"id":1884,"date":"2017-02-15T12:19:51","date_gmt":"2017-02-15T12:19:51","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=1884"},"modified":"2021-10-12T11:12:24","modified_gmt":"2021-10-12T05:42:24","slug":"the-snippet-oncotrack-conducts-largest-academic-industry-research-to-develop-new-biomarkers-for-colon-cancer","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-snippet-oncotrack-conducts-largest-academic-industry-research-to-develop-new-biomarkers-for-colon-cancer","title":{"rendered":"OncoTrack develops new biomarkers for colon cancer"},"content":{"rendered":"

OncoTrack, a public-private consortium supported by the Innovative Medicines Initiative (IMI) joint undertaking, has conducted one of Europe\u2019s largest collaborative academic-industry research projects to develop and assess novel approaches for identification of new markers for colon cancer. Scientists from the OncoTrack Consortium, including researchers from the Max Planck Institute for Molecular Genetics in Berlin and the company Alacris Theranostics, have analyzed tumor samples from cancer patients in a preclinical study. In particular, the scientists looked for biomarkers, i.e. molecules that are typical of the different tumor subgroups and provide valuable information for diagnosis and potential treatment. Among other things, the research team discovered molecules that can predict the effectiveness of two drugs commonly used to treat this disease: Cetuximab and the chemotherapy drug 5FU. The scientists identified the genetic composition of the tumors and analyzed their so-called transcriptome, namely the set of all RNA molecules synthesized in a given tissue. Based on this analysis, they were able to produce a definite molecular fingerprint for all of the tumors. The consortium team identified two such biomarkers, which predict whether either the EGFR inhibitors Cetuximab or the chemotherapy 5FU could trigger a successful response in colorectal cancer.<\/p>\n

To read more, click biomarkers for colon cancer<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"

OncoTrack, a public-private consortium supported by the Innovative Medicines Initiative (IMI) joint undertaking, has conducted one of Europe\u2019s largest collaborative academic-industry research projects to develop and assess novel approaches for identification of new markers for colon cancer. Scientists from the OncoTrack Consortium, including researchers from the Max Planck Institute for Molecular Genetics in Berlin and […]<\/p>\n","protected":false},"author":1,"featured_media":1885,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[41],"tags":[805,137,780,17449],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-1884","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-snippets","tag-biomarkers","tag-cancer","tag-colon-cancer","tag-oncotrack","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"\nOncoTrack's latest Biomaker for Colon Cancer | Colon Cancer's Biomarker<\/title>\n<meta name=\"description\" content=\"OncoTrack, a public-private consortium supported by the Innovative Medicines Initiative (IMI) joint undertaking, has conducted one of Europe\u2019s largest\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-snippet-oncotrack-conducts-largest-academic-industry-research-to-develop-new-biomarkers-for-colon-cancer\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"OncoTrack's latest Biomaker for Colon Cancer | Colon Cancer's Biomarker\" \/>\n<meta property=\"og:description\" content=\"OncoTrack, a public-private consortium supported by the Innovative Medicines Initiative (IMI) joint undertaking, has conducted one of Europe\u2019s largest\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-snippet-oncotrack-conducts-largest-academic-industry-research-to-develop-new-biomarkers-for-colon-cancer\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-02-15T12:19:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-10-12T05:42:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/02\/09021627\/landscape-1445712673-g-bowel-cancer-513088955.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"980\" \/>\n\t<meta property=\"og:image:height\" content=\"490\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"OncoTrack's latest Biomaker for Colon Cancer | Colon Cancer's Biomarker","description":"OncoTrack, a public-private consortium supported by the Innovative Medicines Initiative (IMI) joint undertaking, has conducted one of Europe\u2019s largest","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-snippet-oncotrack-conducts-largest-academic-industry-research-to-develop-new-biomarkers-for-colon-cancer","og_locale":"en_US","og_type":"article","og_title":"OncoTrack's latest Biomaker for Colon Cancer | Colon Cancer's Biomarker","og_description":"OncoTrack, a public-private consortium supported by the Innovative Medicines Initiative (IMI) joint undertaking, has conducted one of Europe\u2019s largest","og_url":"https:\/\/www.delveinsight.com\/blog\/the-snippet-oncotrack-conducts-largest-academic-industry-research-to-develop-new-biomarkers-for-colon-cancer","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2017-02-15T12:19:51+00:00","article_modified_time":"2021-10-12T05:42:24+00:00","og_image":[{"width":980,"height":490,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/02\/09021627\/landscape-1445712673-g-bowel-cancer-513088955.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-snippet-oncotrack-conducts-largest-academic-industry-research-to-develop-new-biomarkers-for-colon-cancer","url":"https:\/\/www.delveinsight.com\/blog\/the-snippet-oncotrack-conducts-largest-academic-industry-research-to-develop-new-biomarkers-for-colon-cancer","name":"OncoTrack's latest Biomaker for Colon Cancer | Colon Cancer's Biomarker","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-snippet-oncotrack-conducts-largest-academic-industry-research-to-develop-new-biomarkers-for-colon-cancer#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-snippet-oncotrack-conducts-largest-academic-industry-research-to-develop-new-biomarkers-for-colon-cancer#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/02\/09021627\/landscape-1445712673-g-bowel-cancer-513088955.jpg","datePublished":"2017-02-15T12:19:51+00:00","dateModified":"2021-10-12T05:42:24+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"OncoTrack, a public-private consortium supported by the Innovative Medicines Initiative (IMI) joint undertaking, has conducted one of Europe\u2019s largest","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-snippet-oncotrack-conducts-largest-academic-industry-research-to-develop-new-biomarkers-for-colon-cancer"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-snippet-oncotrack-conducts-largest-academic-industry-research-to-develop-new-biomarkers-for-colon-cancer#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/02\/09021627\/landscape-1445712673-g-bowel-cancer-513088955.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/02\/09021627\/landscape-1445712673-g-bowel-cancer-513088955.jpg","width":980,"height":490},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/02\/09021627\/landscape-1445712673-g-bowel-cancer-513088955-300x150.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Biomarkers<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">colon cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">OncoTrack<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Biomarkers<\/span>","<span class=\"advgb-post-tax-term\">Cancer<\/span>","<span class=\"advgb-post-tax-term\">colon cancer<\/span>","<span class=\"advgb-post-tax-term\">OncoTrack<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 9 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Feb 15, 2017","modified":"Updated on Oct 12, 2021"},"absolute_dates_time":{"created":"Posted on Feb 15, 2017 12:19 pm","modified":"Updated on Oct 12, 2021 11:12 am"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1884","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=1884"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1884\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/1885"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=1884"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=1884"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=1884"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=1884"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=1884"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}